Jump to content

GlaxoSmithKline (GSK) share price: Q2 earnings preview


Recommended Posts

GlaxoSmithKline Q2 revenue is expected to show revenue growth from newer drugs partially offset by increased generic competition in older drugs.

TraderSource: Bloomberg
 
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021 

When is GlaxoSmithKline earnings date?

The GlaxoSmithKline (GSK) earnings release date is scheduled for the 28 July 2021. The scheduled results will cover the groups second quarter and half-year earnings.

 

GSK results preview: What does the street expect?

While GlaxoSmithKline (in partnership with Sanofi Pasteur) look to stage three trials of their Covid-19 vaccine, the company has not yet released a vaccine to market. The global rollout of Covid-19 vaccines (by competitors) looks to have disrupted the course of other vaccine programmes in key markets such as the US and the UK for GSK.

Revenue for second quarter (Q2) 2021 is expected to be bolstered by sales of newer drugs in the respiratory and HIV segments, with a partial offset from older drugs which are finding increased competition through generic offerings.

In terms of the upcoming results, a mean of analyst estimates compiled by Refinitiv data arrive at the following:

How to trade the GlaxoSmithKline results

 

GlaxoSmithKline chartSource: Refinitiv

 

A Refinitiv poll of analyst ratings arrive have a long term consensus rating of ‘buy’ for GlaxoSmithKline with a target price $47.87.

GlaxoSmithKline (ADR) share price: technical analysis

 

GlaxoSmithKline (ADR) chartSource: IG

The share price of GlaxoSmithKline continues to trade in an uptrend which has been in place since the beginning of March 2021. The price has however started to correct from near term highs.

The correction sees the price now testing support at the 38.85 level. Traders looking for long entry might prefer to see a bullish price reversal around current levels accompanied by a sharper move out of oversold territory by the Stochastic oscillator. In this scenario, the recent high at 40.55 would become the initial resistance target, while a close below 38.35 could be used as a stop loss consideration for the trade.

However should a bullish price reversal not manifest and we see the price move to close below both the 38.85 and 38.35 support levels, this could instead be a suggestion that the uptrend has failed and perhaps a new downtrend for the share price is forming.

In Summary

  • GSK reports Q2 2021 results on the 28 July
  • Q2 revenue of $10.433 billion (+10.27% YoY) is expected
  • Q2 EBITDA of $2.855 billion (-8.91% YoY) are expected
  • EPS $0.51 (+10.87% YoY) in the Q2 are expected
  • The average long term broker rating for GSK is a ‘buy’
  • The share price of GSK is testing support as it finds itself in a short-term correction of a longer-term uptrend
Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • image.png

  • Posts

    • Elliott Wave Analysis Indices: Elliott Wave Analysis Indices: SP 500 & NASDAQ v of (v) of iii) of 1 of (5) of 3) of I.  NVDA Earnings has been the center of attention late in the last session and has created volatile intraday price action, however we are still on track for all Elliott wave counts, that is looking for the top of Wave iii).  The European and Asia indices will track the US indices on an intraday basis, so they too are in much the same Elliott wave patterns. Video Chapters  00:00 SP 500 (SPX), SPY ETF 08:45 NASDAQ (NDX), QQQ ETF 12:04 Russell 2000 (RUT) IWM 13:18 DAX 40 (DAX) 16:57 FTSE 100 UKX (UK100) 18:11 S&P/ASX 200 (XJO) 24:06 End Analyst Peter Mathers TradingLounge™ Australian Financial Services Licence - AFSL 317817 Source: tradinglounge      
    • Currently, Bitget wallet stands as one of the most suitable decentralised wallets. It is built with everything incorporated into it, it is the hub of a handy suite of tools that cater to every crypto enthusiast.  It is interesting to note that it has been over 6 years since the platform commenced rendering crypto services. In commemoration of its 6th anniversary, an event has been set up to let its users earn some good amount and merch along with.  The criteria for participation is relatively easy. You just need to join to win exclusive merch, firstly by following @BitgetWallet while adding a RT + Comment #BitgetWallet6Years’’ Similarly, you can give insightful feedback about Bitget Wallet and stand a chance to win Bitget exclusive merch like T-shirt, Cap, Hoodie and Wristband. I will be jumping on this event too. Such an easy peasy way to earn.
    • Basically, they're letting creators mint NFTs and other digital stuff across multiple blockchains at once. Holograph isn't the only one trying to build bridges between blockchains. Projects like Omnibridge and Wormhole are also in the game, each with their own way of moving your digital assets around.  While Holograph focuses on this "native minting" thing across chains, other projects might be a better fit depending on what you need. Doing your research is key! Definitely something to consider. While Holograph recently scored a cool $11 million in funding, omnichain functionality is still pretty new. They've also got some interesting features, just landed on Bitget, and seems to be building an empire state. There could be bumps in the road, so be sure to do your own research and understand the potential risks. So, what do you think? Is Holograph the future of NFTs, or is it just a bunch of hype? Have you tried any other cross-chain solutions? Let's hear your thoughts in the comments!
×
×
  • Create New...
us